Bacteriophage compositions and methods of use thereof

Inventors

PAROS, Mike • HONAKER, Ryan • HOBBS, Zachary Alan • RICHTER, Manuela • MOKRES, Lucia • KADIJA, Ermir

Assignees

Locus Biosciences Inc

Abstract

The present application provides bacteriophage compositions, and methods of treating or preventing bacterial infections using the bacteriophage compositions. The bacteriophage compositions can inhibit bacterial adhesion, invasion, and/or colonization in epithelial cells. The compositions and methods described herein are useful for treating or preventing mastitis in dairy cows.

Core Innovation

The patent describes bacteriophage compositions comprising at least two bacteriophage that target Gram-negative bacteria, together with a buffering agent, for treating or preventing a bacterial infection in an individual in need thereof. The bacteriophage are defined by genome sequence similarity, including bacteriophage having genome sequences having at least about 95% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

The patent also describes administering a composition to inhibit bacteria adhesion, invasion, and/or colonization of epithelial cells of an individual in need thereof. In some embodiments, the target is narrowed to E. coli and embodiments include at least three or more bacteriophages.

Beyond in vivo treatment, the patent describes inhibiting bacteria growth in a target composition by contacting the target composition with an effective amount of a composition comprising at least two bacteriophage targeting Gram-negative bacteria and a buffering agent. In compositions described in the claims, the number of bacteriophages can be increased to at least four, and specific bacteriophage components p0031, p0032, p0033, and p0034 are included alongside the buffering agent.

Claims Coverage

The independent claims cover five main inventive areas. Across the independent claims, the central inventive features are the use of bacteriophage targeting Gram-negative bacteria with genome sequences having at least about 95% sequence identity to defined SEQ ID NOs, together with a buffering agent, minimum phage-count thresholds, and specific p0031/p0032/p0033/p0034 composition embodiments.

Across the independent claims, the coverage centers on compositions and methods that use multiple Gram-negative targeting bacteriophage defined by genome sequence identity at least about 95% to specified SEQ ID NOs together with a buffering agent. The claim set covers treating or preventing bacterial infection, inhibiting adhesion, invasion, and/or colonization of epithelial cells, inhibiting bacteria growth, and compositions requiring at least four bacteriophage, including a p0031/p0032/p0033/p0034 embodiment.

Stated Advantages

Documented Applications